GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Net Interest Income

OncoZenge AB (OSTO:ONCOZ) Net Interest Income : kr-0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. OncoZenge AB's net interest income for the three months ended in Dec. 2024 was kr0.00 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.00 Mil.

OncoZenge AB Net Interest Income Historical Data

The historical data trend for OncoZenge AB's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Net Interest Income Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
- - - - -

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OncoZenge AB Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB Net Interest Income Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Net Interest Income
Comparable Companies
XSAT:CHOSA OSTO:ACOU OSTO:EXPRS2 XSAT:NIDHOG OSTO:COMBI OSTO:SIMRIS B OSTO:SPRINT OSTO:MODTX OSTO:BIOVIC B OSTO:BIOSGN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
8LY:Germany
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
Website
https://www.oncozenge.com
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines